5-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)噻唑 | 1086111-09-2

• 物质功能分类: 化学试剂 - 有机试剂 - 硼烷
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硼酸衍生物
• 中文名称: 5-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)噻唑
• 中文别名: 5-(4,4,5,5-四甲基-1,3,2-二恶硼烷-2-基)噻唑；噻唑-5-硼酸频哪醇酯
• 英文名称: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole
• 英文别名: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-thiazole；thiazol-5-ylboronic acid pinacol ester；thiazole-5-boronic acid pinacol ester
• CAS: 1086111-09-2
• 化学式: C₉H₁₄BNO₂S
• mdl: MFCD10697440
• 分子量: 211.093
• InChiKey: ODYWLZYOVWNCGN-UHFFFAOYSA-N

物化性质

• 熔点：
  98 °C
• 沸点：
  304.7±15.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.44
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  59.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险标志：
  GHS06
• 危险性描述：
  H301
• 危险性防范说明：
  P301 + P310
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-thiazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-thiazole
CAS number: 1086111-09-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H14BNO2S
Molecular weight: 211.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)噻唑 在 potassium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 噻唑
  参考文献：
  名称：

  （杂）芳基硼酸酯的原脱硼：直接与预水解途径和自/自催化

  摘要：

  一系列硼酸酯的碱催化水解（ArB(OR) 2 → ArB(OH) 2）和原脱硼化（ArB(OR) 2 → ArH）的动力学和机理，包括八种不同的多元醇和 10 种多氟芳基和杂芳基部分，已通过原位和停流 NMR 光谱（19 F、1 H 和11 B）、pH 速率依赖性、同位素夹带进行了研究，2H KIE 和 KS-DFT 计算。该研究揭示了硼酸酯在碱性水-有机条件下的现象稳定性非常微妙。与通常的假设相反，与相应的硼酸相比，酯化不一定赋予更高的稳定性。此外，酯水解为硼酸可以是整个原脱硼过程的主要成分，当 pH 值接近硼酸的 p K a时，自催化、自催化和氧化（酚类）催化作用增强酯。

  DOI：

  10.1021/jacs.1c06863
• 作为产物：
  描述：

  3,5-二甲基异恶唑-4-硼酸频哪醇酯 在 正丁基锂 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 正己烷 为溶剂， 反应 3.5h， 生成 5-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)噻唑
  参考文献：
  名称：

  （杂）芳基硼酸酯的原脱硼：直接与预水解途径和自/自催化

  摘要：

  一系列硼酸酯的碱催化水解（ArB(OR) 2 → ArB(OH) 2）和原脱硼化（ArB(OR) 2 → ArH）的动力学和机理，包括八种不同的多元醇和 10 种多氟芳基和杂芳基部分，已通过原位和停流 NMR 光谱（19 F、1 H 和11 B）、pH 速率依赖性、同位素夹带进行了研究，2H KIE 和 KS-DFT 计算。该研究揭示了硼酸酯在碱性水-有机条件下的现象稳定性非常微妙。与通常的假设相反，与相应的硼酸相比，酯化不一定赋予更高的稳定性。此外，酯水解为硼酸可以是整个原脱硼过程的主要成分，当 pH 值接近硼酸的 p K a时，自催化、自催化和氧化（酚类）催化作用增强酯。

  DOI：

  10.1021/jacs.1c06863

文献信息

• [EN] INHIBITORS OF KRAS G12C<br/>[FR] INHIBITEURS DE K-RAS G12C
  申请人：ARAXES PHARMA LLC

  公开号：WO2015054572A1

  公开（公告）日：2015-04-16

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了作为G12C突变KRAS蛋白抑制剂活性的化合物。这些化合物具有以下结构（I）：或其药用可接受的盐、互变异构体、前药或立体异构体，其中R1、R2a、R3a、R3b、R4a、R4b、G1、G2、L1、L2、m1、m2、A、B、W、X、Y、Z和E如本文所定义。还提供了与制备和使用这些化合物相关的方法，包括含有这些化合物的药物组合物以及调节G12C突变KRAS蛋白活性以治疗癌症等疾病的方法。
• [EN] ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'AMINE ARYL-BIPYRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE LA PHOSPHATIDYLINOSITOL PHOSPHATE KINASE
  申请人：PETRA PHARMA CORP

  公开号：WO2019126733A1

  公开（公告）日：2019-06-27

  The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I): wherein A, X, Y, Z, Q, R1, R2, R3, R4, R5, and n are described herein.

  这项发明涉及PI5P4K抑制剂，用于治疗癌症、神经退行性疾病、炎症性疾病和代谢性疾病，其化学式为（I）：其中A、X、Y、Z、Q、R1、R2、R3、R4、R5和n如本文所述。
• [EN] CD38 INHIBITORS<br/>[FR] INHIBITEURS DE CD38
  申请人：MITOBRIDGE INC

  公开号：WO2021207186A1

  公开（公告）日：2021-10-14

  One embodiment of the invention is a compound represented by Formula I: or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are CD38 inhibitors, which can be used to treat a disease or condition in a subject that benefits from an increase in NAD+ or to treat a mitochondrial disorder in a subject.

  该发明的一个实施例是由化学式I表示的化合物：或其药用可接受的盐。化学式I中的变量在此处定义。化学式I的化合物是CD38抑制剂，可用于治疗需要增加NAD+的受试者的疾病或病况，或用于治疗受试者的线粒体疾病。
• [EN] STRAD-BINDING AGENTS AND USES THEREOF<br/>[FR] AGENTS DE LIAISON À STRAD ET LEURS UTILISATIONS
  申请人：UNIV CALIFORNIA

  公开号：WO2021155004A1

  公开（公告）日：2021-08-05

  Disclosed herein, inter alia, are compounds for binding STRAD pseudokinase and uses thereof.

  披露的内容包括，但不限于，用于结合STRAD假激酶的化合物及其用途。
• [EN] 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS<br/>[FR] DÉRIVÉS DE 1-BENZYL-2-IMINO-4-PHÉNYL-5-OXOIMIDAZOLIDINE UTILISÉS EN TANT QU'INHIBITEURS DE LA PROTÉASE DU VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2019075291A1

  公开（公告）日：2019-04-18

  The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herin. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.

  这项发明提供了一种如下式的化合物：或其药学上可接受的盐。该发明还提供了包含如下式化合物的药物组合物，制备如下式化合物的方法，使用如下式化合物治疗HIV病毒的增殖、治疗艾滋病或延缓哺乳动物艾滋病症状发作的治疗方法。